Tag: psychiatric disorders
University of Sydney spinout bags $273m for psychiatric drug dev’t
Kinoxis Therapeutics, a University of Sydney spinoff, announced a partnership with German pharmaceutical company Boehringer Ingelheim to develop precision therapies that target oxytocin aimed at enhancing the quality of life for people with psychiatric disorders.
Featured Article
What spending reveals about downstream consumer demand for manufactured goods
For manufacturers supplying consumer-facing markets, understanding demand conditions has become increasingly important in an environment shaped by cautious spending, rising costs and intense competition.
